Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are sensitive to treatment with poly(ADP) ribose...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ha, Kyungsoo, Fiskus, Warren, Choi, Dong Soon, Bhaskara, Srividya, Cerchietti, Leandro, Devaraj, Santhana G. T., Shah, Bhavin, Sharma, Sunil, Chang, Jenny C., Melnick, Ari M., Hiebert, Scott, Bhalla, Kapil N.
Format:	Artigo
Language:	Inglês
Published:	Impact Journals LLC 2014
Subjects:	Research Paper
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4170637/ https://ncbi.nlm.nih.gov/pubmed/25026298
Tags:	Add Tag No Tags, Be the first to tag this record!

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Similar Items